APA (7th ed.) Citation

Pavel Burda, Alzbeta Hlavackova, Vendula Polivkova, Nikola Curik, Adam Laznicka, Jitka Krizkova, . . . Katerina Machova Polakova. (2024). Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events. Elsevier.

Chicago Style (17th ed.) Citation

Pavel Burda, Alzbeta Hlavackova, Vendula Polivkova, Nikola Curik, Adam Laznicka, Jitka Krizkova, Jiri Suttnar, Pavel Klener, and Katerina Machova Polakova. Imatinib Therapy of Chronic Myeloid Leukemia Significantly Reduces Carnitine Cell Intake, Resulting in Adverse Events. Elsevier, 2024.

MLA (9th ed.) Citation

Pavel Burda, et al. Imatinib Therapy of Chronic Myeloid Leukemia Significantly Reduces Carnitine Cell Intake, Resulting in Adverse Events. Elsevier, 2024.